Uses
Inotuzumab (Humanized Anti-CD22 Recombinant Antibody) is a humanized IgG4, κ antibody that targets human CD22. Inotuzumab can be linked to a toxic agent ozogamicin as an antibody-drug conjugate (ADC). Inotuzumab can be used for the research of acute lymphoblastic leukemia and non-Hodgkin lymphoma[1][2][3][4].
in vivo
Inotuzumab ozogamicin (100 μg/kg, i.p., twice a week for 2 weeks) combined with Venetoclax (HY-15531), Dexamethasone (HY-14648) induces long-term survival in murine patient-derived xenograft (PDX) models[3].
Inotuzumab (0.27, 3.2 mg/kg, i.p., a single dose for 400 h) inhibits tumor growth in mouse xenograft models[4].
| Animal Model: | Mouse xenograft models[4].
|
| Dosage: | 0.27, 3.2 mg/kg |
| Administration: | i.p., a single dose for 400 h |
| Result: | Decreased the tumor volume in mouse xenograft models. |
References
[1] Aujla A, et al. Inotuzumab ozogamicin in clinical development for acute lymphoblastic leukemia and non-Hodgkin lymphoma. Biomark Res. 2019 Apr 11;7:9. DOI:
10.1186/s40364-019-0160-4[2] Wynne J, et al. Inotuzumab: from preclinical development to success in B-cell acute lymphoblastic leukemia. Blood Adv. 2019 Jan 8;3(1):96-104. DOI:
10.1182/bloodadvances.2018026211[3] Kirchhoff H, et al. Venetoclax and dexamethasone synergize with inotuzumab ozogamicin-induced DNA damage signaling in B-lineage ALL. Blood. 2021 May 13;137(19):2657-2661. DOI:
10.1182/blood.2020008544[4] Betts AM, et al. Preclinical to Clinical Translation of Antibody-Drug Conjugates Using PK/PD Modeling: a Retrospective Analysis of Inotuzumab Ozogamicin. AAPS J. 2016 Sep;18(5):1101-1116. DOI:
10.1208/s12248-016-9929-7
